Press Releases - Afimmune

June 2, 2026

Afimmune Reports Positive Phase 2 Results for Epeleuton in Sickle Cell Disease, Reducing Vaso-Occlusive Crisis Rate by 57.4%

· Epeleuton reduced the annualised rate of vaso-occlusive crises (VOCs) leading to a healthcare visit by 57.4% versus the prior-year baseline (p=0.0001). · 62.1% of evaluable […]

November 5, 2025

Afimmune to host session before and present at the 67th American Society of Hematology (ASH) Annual Meeting after completing Sickle Cell Disease trial enrolment.

Dublin, Ireland, 5 November 2025: Afimmune, a clinical stage biopharmaceutical company developing novel rare disease therapeutics, today announced that enrolment has successfully completed in the first clinical trial […]

September 19, 2024

Epeleuton for Sickle Cell Disease receives key US patent grant

Dublin, Ireland, 18th September 2024 – Afimmune, a clinical stage drug discovery and development company, today announced that the U.S. Patent and Trademark Office has issued […]

April 19, 2024

Afimmune Announces Partnership in Sickle Cell Disease Research with Pathway to Cures

Dublin, Ireland, 19 April 2024: Afimmune announced today its collaborative partnership with Pathway to Cures (P2C) to support the development of Epeleuton as a potential therapeutic […]

November 8, 2023

Afimmune to present at the American Society of Hematology (ASH) Annual Meeting after initiating recruitment in Sickle Cell Disease trial

Dublin, Ireland, 8 November 2023: Afimmune, a clinical stage biopharmaceutical company developing novel rare disease therapeutics, today announced that recruitment has commenced in the first clinical […]

September 18, 2023

Afimmune’s Epeleuton is granted both FDA Rare Pediatric Disease and Fast Track Designations for the treatment of Sickle Cell Disease

Dublin, Ireland, 18 September 2023: Afimmune, a clinical stage biopharmaceutical company developing novel rare disease therapeutics, today announced that the U.S. Food and Drug Administration (FDA) has granted […]

June 19, 2023

Afimmune joins the Sickle Cell Disease Association of America’s Collaboration of Advocates for Research, Education and Science (C.A.R.E.S.) Consortium

Dublin, Ireland, 19 June 2023: Afimmune, a clinical stage biopharmaceutical company developing novel rare disease therapeutics, today announced it has been invited to join the Sickle Cell Disease […]

June 5, 2023

Data Showing Epeleuton Reduces Endothelial Adhesion Of Red Blood Cells From Sickle Cell Disease Patients Will Be Presented At The EHA 2023 Congress

Dublin, Ireland, 5 June 2023: Afimmune, a privately held, clinical stage biopharmaceutical company, today announced that results of its investigational drug Epeleuton will be presented at the European Hematology […]

March 29, 2023

Afimmune to Host KOL Webinar on Sickle Cell Disease: The Changing Landscape and Need for New Treatments

Dublin, Ireland, 29 Mar 2023: Afimmune, a privately held, clinical stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced it will host a […]

January 4, 2023

Afimmune Confirm Alignment with FDA on Planned Pivotal Trial of Epeleuton in Sickle Cell Disease Patients

Afimmune looking to initiate Pivotal study in 2023 Dublin, Ireland, 4 January 2023: Afimmune, a privately held, clinical stage biopharmaceutical company developing novel therapeutics for the […]

September 19, 2022

Epeleuton receives orphan-drug designation for Sickle Cell Disease from the EMA

Dublin, Ireland, 19 September 2022: Afimmune, a privately held, clinical stage biopharmaceutical company, today announced that the European Medicines Agency (EMA) has granted orphan drug designation […]

July 19, 2022

Epeleuton receives orphan-drug designation for Sickle Cell Disease from the FDA

Dublin, Ireland, 19 July 2022: Afimmune, a privately held, clinical stage biopharmaceutical company, today announced that the Food and Drug Administration (FDA) in the United States […]

June 10, 2022

Data Showing Epeleuton As A Potential Treatment For Sickle Cell Disease Will Be Presented At The EHA 2022 Congress

Dublin, Ireland, 10 June 2022: Afimmune, a privately held, clinical stage biopharmaceutical company, today announced that results of its investigational drug Epeleuton will be presented at […]

May 13, 2022

EPELEUTON, A NOVEL SYNTHETIC SECOND GENERATION W-3 FATTY ACID, PROTECTS HUMANIZED SICKLE CELL MICE AGAINST HYPOXIA/REOXYGENATION ORGAN DAMAGE

Presentation during EHA2022: All (e)Poster presentations will be made available as of Friday, June 10, 2022 (09:00 CEST) and will be accessible for on-demand viewing until […]

August 26, 2021

Afimmune’s Epeleuton shows large decreases in viral load and pathological changes in COVID-19 study

Epeleuton decreases viral titres and SARS-CoV-2 RNA and histopathological damage in the upper and lower respiratory tract Dublin, Ireland, 26th August 2021 – Afimmune, a clinical stage drug discovery […]